Nickan Research Institute Journal of Renal Injury Prevention 2345-2781 15 3 2026 09 01 Renoprotective bioactives; evaluating the efficacy of nutraceuticals in mitigating inflammation and oxidative stress in chronic kidney disease e38764 e38764 10.34172/jrip.38764 EN Hussein S Janabi https://orcid.org/0009-0008-4169-3858 Abdul Amir H. Kadhum https://orcid.org/0000-0003-4074-9123 Asaad Abass Fadhel Khalif Hussein Ali Al-Bahrani https://orcid.org/0000-0002-9637-3359 Journal Article 10.34172/jrip.38764 2026 04 04 2026 07 15 Chronic kidney disease (CKD) characterizes one of the most pressing public health challenges of the 21th century. This disease characterized by a progressive and often irreversible loss of kidney function and structure that terminates in end-stage renal disease (ESRD), that requiring dialysis or transplantation. The global prevalence of chronic renal failure continues to rise, driven largely by the epidemics of diabetes mellitus and hypertension, since the present standard of care remains primarily conducted on slowing progression rather than reversing damage. Although pharmacological interventions like renin-angiotensin-aldosterone system (RAAS) inhibitors and sodium-glucose cotransporter-2 (SGLT2) inhibitors have demonstrated significant efficiency in maintaining glomerular filtration rate, a substantial residual risk remains for many patients. This therapeutic gap has prompted intense scientific interest in adjunctive therapies, particularly directing on the underlying molecular drivers of kidney injury. Amongst these drivers, chronic low-grade inflammation and oxidative stress stand out as central pathological mechanisms that stimulate the vicious cycle of nephron loss and fibrosis. Consequently, the exploration of kidney protective bioactives, generally categorized under the group of nutraceuticals that has identified as a hopeful frontier in nephrology. Additionally, these bioactive complexes, derived from food sources or herbal medicinal, present the capability to alter the intricate signaling pathways accompanying by kidney inflammation and redox imbalance, providing a complementary modality to standard pharmacotherapy.